# Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

> **NCT00729469** · PHASE3 · COMPLETED · sponsor: **Shionogi** · enrollment: 919 (actual)

## Conditions studied

- Atrophy
- Vaginal Diseases

## Interventions

- **DRUG:** Ospemifene 60 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00729469
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 919 (ACTUAL)
- **Last updated:** 2018-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729469, "Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*